CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions J Med Internet Res 2011;13(4):e126 URL: <u>http://www.jmir.org/2011/4/e126/</u> doi: 10.2196/jmir.1923 PMID: 22209829

* Required

Your name * First Last

Parish, Michelle Burke

Primary Affiliation (short), City, Country * University of Toronto, Toronto, Canada

Univeristy of California, Davis, Davis California

Your e-mail address * abc@gmail.com

mbparish@ucdavis.edu

Title of your manuscript *

Provide the (draft) title of your manuscript.

Clinical Outcomes of Asynchronous v Synchronous Telepsychiatry in Primary Care: A Randomized Controlled Trial

You're editing your response. Sharing this URL allows others to also edit your response.

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Asynchronous Telepsychiatry

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English, Spanish

URL of your Intervention Website or App


e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.



Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Anxiety, Depression, Mood disorder, Substance

Primary Outcomes measured in trial * comma-separated list of primary outcomes reported in the trial

Clinical Global Impressions scale [CGI] and the

Secondary/other outcomes


Are there any other outcomes the intervention is expected to affect?

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

FILL OUT A NEW RESPONSE

4 of 52



Approx. Percentage of Users (starters) still using the app as recommended after 3 months *

You're editing your response. Sharing this URL allows others to also edit your response.	FILL OUT A NEW RESPONSE
91-100%	
81-90%	
O 71%-80%	
61-70%	
51-60%	
O 41-50%	
31-40%	
O 21-30%	
0 11-20%	
0-10%	
O unknown / not evaluated	

Overall, was the app/intervention effective? *
yes: all primary outcomes were significantly better in intervention group vs control
O partly: SOME primary outcomes were significantly better in intervention group vs control
no statistically significant difference between control and intervention
O potentially harmful: control was significantly better than intervention in one or more outcomes
O inconclusive: more research is needed
O Other:
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
At which stage in your article preparation are you currently (at the time you fill in this form)
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission
At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet
 At which stage in your article preparation are you currently (at the time you fill in this form) not submitted yet - in early draft status not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer comments

You're editing your response. Sharing this URL allows others to also edit your response.

Journal * If you already know where you will submit this paper (or if it is already submitted), please provide the
journal name (if it is not JMIR, provide the journal name under "other")
O not submitted yet / unclear where I will submit this
Journal of Medical Internet Research (JMIR)
JMIR mHealth and UHealth
JMIR Serious Games
JMIR Mental Health
JMIR Public Health
JMIR Formative Research
O Other JMIR sister journal
O Other:
Is this a full powered effectiveness trial or a pilot/feasibility trial? * Pilot/feasibility Fully powered
Manuscript tracking number * If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR) on ms number (yet) / not (yet) submitted to / published in JMIR
Other 24047-400713-1 You're editing your response. Sharing this URL allows others to also FILL OUT A NEW edit your response. FILL OUT A NEW
edit your response. RESPONSE

TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title


1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

🔵 yes

Other:

1a-i) Identify the mode of delivery in the title


Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.



Does your paper address subitem 1a-i?*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

You're editing your response. Sharing this URL allows others to also edit your response.



	1b) ABSTRACT: Structured s conclusions NPT extension: Description of experin status.		-	-						
	1b-i) Key features/functionali	ties/co	mponen	ts of the	e interve	ention ar	nd			
comparator in the METHODS section of the ABSTRACT										
Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)										
		1	2	3	4	5				
					-					
	subitem not at all important	0	0	0	0	0	essential			
	Does your paper address sub Copy and paste relevant sections fror			6						
	this" to indicate direct quotes from yo information not in the ms, or briefly ex "Patients were treated by their PC University of California Davis Hea 6 months for up to 2 years using	our manus xplain wh CPs usin alth telep	script), or e y the item og a collal osychiatri	elaborate o is not app porative o	on this iter licable/rel care mod	n by provic levant for y lel in cons	ling additional our study sultation with			
	this" to indicate direct quotes from yo information not in the ms, or briefly ex "Patients were treated by their PC University of California Davis Hea	our manus xplain wh CPs usin alth telep ATP or S ment in t in the al sian-assis act what	the ME bstract, e.g. the main p	THODS , use phr ion numb	on this iter licable/rel care mod consulte section ases like " er and exp	n by provid levant for y lel in cons d with the of the A fully autom ertise of p	ling additional our study sultation with e patients every BSTRACT nated" vs. roviders involved,			
	this" to indicate direct quotes from yo information not in the ms, or briefly ex "Patients were treated by their PO University of California Davis Hea 6 months for up to 2 years using 1b-ii) Level of human involver Clarify the level of human involvemen "therapist/nurse/care provider/physic if any). (Note: Only report in the abstra	our manus xplain wh CPs usin alth telep ATP or S ment in t in the al sian-assis act what	the ME bstract, e.g. the main p	THODS , use phr ion numb	on this iter licable/rel care mod consulte section ases like " er and exp	n by provid levant for y lel in cons d with the of the A fully autom ertise of p	ling additional our study sultation with e patients every BSTRACT nated" vs. roviders involved,			

R.,

Does your paper address subitem 1b-ii? Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study										
based (self-ass	essmen	ıt) vs. fad	ce-to-fa	ce					
S sectio	on of the	e ABSTR	RACT							
closed use onents (as h question (open-labo hich treath the level o participant	ergroup tria s part of th nnaires (as el trial) is ment is be of blinding s can self-	al), and cla he interver s common a type of c ing admin instead of enrol). (No	arify if this ntion or for in web-ba linical tria istered. To "open", as ote: Only ro	was a pur assessme sed trials) I in which I avoid con of open" in eport in the	ely web-based ent). Clearly say if . Note: In both the fusion, use web-based trials e abstract what					
1	2	3	4	5						
0	0	0	0	0	essential					
	based (DS section ited (onlin closed use bonents (ar h question (open-labo hich treat the level of boarticipant formation	based (self-ass based (self-ass S section of the ited (online vs. offlin closed usergroup tria onents (as part of th h questionnaires (as (open-label trial) is a hich treatment is be the level of blinding participants can self- formation is missing	based (self-assessmen DS section of the ABSTR ited (online vs. offline), e.g., fr closed usergroup trial), and cla ponents (as part of the interver h questionnaires (as common (open-label trial) is a type of c hich treatment is being admin the level of blinding instead of participants can self-enrol). (N formation is missing from the	based (self-assessment) vs. face based (self-assessment) vs. face DS section of the ABSTRACT ited (online vs. offline), e.g., from an ope closed usergroup trial), and clarify if this bonents (as part of the intervention or for th questionnaires (as common in web-ba (open-label trial) is a type of clinical tria hich treatment is being administered. To the level of blinding instead of "open", as participants can self-enrol). (Note: Only re formation is missing from the main body	based (self-assessment) vs. face-to-fa based (self-assessment) vs. face-to-fa DS section of the ABSTRACT ited (online vs. offline), e.g., from an open access v closed usergroup trial), and clarify if this was a pur- bonents (as part of the intervention or for assessme h questionnaires (as common in web-based trials). (open-label trial) is a type of clinical trial in which t hich treatment is being administered. To avoid con the level of blinding instead of "open", as "open" in participants can self-enrol). (Note: Only report in the formation is missing from the main body of text, co					

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sul			etro et (in	oludo quot	oo in quot	ntion marka "li
Copy and paste relevant sections from this" to indicate direct quotes from you information not in the ms, or briefly e	our manus	cript), or e	laborate o	on this iter	n by provic	ling additional
Vour opour						
Your answer						
rour answer						
1b-v) CONCLUSIONS/DISCU				0		
	for negati jed), and t ake and di	ive trials: [he interve scuss rea:)iscuss th ntion was sons. (Not	e primary not used, e: Only rep	outcome - discuss wh port in the a	nether negative abstract what
1b-v) CONCLUSIONS/DISCU Conclusions/Discussions in abstract negative (primary outcome not chang results are attributable to lack of upto	for negati jed), and t ake and di	ive trials: [he interve scuss rea:)iscuss th ntion was sons. (Not	e primary not used, e: Only rep	outcome - discuss wh port in the a	nether negative abstract what
1b-v) CONCLUSIONS/DISCU Conclusions/Discussions in abstract negative (primary outcome not chang results are attributable to lack of upto	for negati Jed), and t ake and di Jation is m	ive trials: I he interve scuss reas hissing fro	Discuss th ntion was sons. (Not m the mai	e primary not used, e: Only rep	outcome - discuss wh port in the a text, consid	nether negative abstract what
1b-v) CONCLUSIONS/DISCU Conclusions/Discussions in abstract negative (primary outcome not chang results are attributable to lack of upta main paper is reporting. If this inform	for negati Jed), and t ake and di Jation is m	ive trials: I he interve scuss reas hissing fro	Discuss th ntion was sons. (Not m the mai	e primary not used, e: Only rep	outcome - discuss wh port in the a text, consid	nether negativ abstract what der adding it)
1b-v) CONCLUSIONS/DISCU Conclusions/Discussions in abstract negative (primary outcome not chang results are attributable to lack of upta main paper is reporting. If this inform	for negati led), and t ake and di ation is m 1 0	ive trials: I he interve scuss reas nissing fro 2 0	Discuss th Intion was sons. (Not m the mai 3	e primary not used, re: Only rep n body of 4	outcome - discuss wh port in the text, consid 5	nether negative abstract what der adding it) essential

E

INTRODUCTION 2a) In INTRODUCTION: Scientific background and explanation of rationale 2a-i) Problem and the type of system/solution Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5) 1 2 3 5 4 \bigcirc \bigcirc subitem not at all important essential Clear selection Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Despite such success with STP being the current standard telepsychiatry practice [8, 9], administrative and technical challenges exist, especially around scheduling of telepsychiatrists and patients [10, 11], and STP itself is simply a virtual extension of inperson care which cannot be scaled to enable one physician to see more patients."

You're editing your response. Sharing this URL allows others to also edit your response.

2a-ii) Scientific background, rationale: What is known about the (type of) system								
Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.								
	1	2	3	4	5			
subitem not at all important	۲	0	0	0	0	essential		
					C	Clear selection		

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Asynchronous care makes use of a completely virtual care model with the transmission of clinical information via web applications for review by a specialist at a later time [12, 13] and has the potential to scale and enable psychiatrists to be involved in the treatment of more patients than with STP. ATP can also reduce the impact of poor bandwidth and connectivity issues seen with STP, providing potentially better access to more diverse patient populations."

2b) In INTRODUCTION: Specific objectives or hypotheses

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We hypothesized that compared to the participants in the STP arm, participants in the ATP arm would show a better clinical trajectory over the course of treatment, as measured by

You're editing your response. Sharing this URL allows others to also edit your response.

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study was a randomized controlled clinical trial.."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Thus, the DSMB recommended the primary end point be at 12 months and advised subsequent enrollment be limited to 12-month follow-up. The 12-month follow-up became the primary analysis of interest and the Institutional Review Board (IRB) documentation was modified in April 2018. The last 18 patients were enrolled for one year only. "

You're editing your response. Sharing this URL allows others to also edit your response.

3b-i) Bug fixes, Downtimes, Content Changes Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			

Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Thirty-six primary care physicians (PCPs) were recruited as referring providers. We placed an alert in the electronic medical record system to remind PCPs about the trial. Patients learned of the study through their PCP or from advertisements at the referring clinics. All participants were 18 or older, able to give written informed consent, and referred by PCPs as possibly having one or more non-urgent mental health diagnoses, mainly a mood disorder, anxiety disorder, or substance/alcohol use disorder(s)."

You're editing your response. Sharing this URL allows others to also edit your response.

4a-i) Computer / Internet literacy Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.										
	1	2	3	4	5					
subitem not at all important	0	0	0	0	0	essential				

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"web-based asynchronous vs_synchronous" Asynchronous telepsychiatry vs_Synchronous

You're editing your response. Sharing this URL allows others to also edit your response.

4a-iii) Information giving during recruitment Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			

Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer


4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study was a randomized controlled clinical trial at 3 community-based primary care clinics in the Sacramento area ... a Federally Qualified Health Center that treats primarily Spanish-speaking patients as one of our referring clinics."

You're editing your response. Sharing this URL allows others to also edit your response.



5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and

owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

You're editing your response. Sharing this URL allows others to also edit your response.

Does your paper address subitem 5-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Your answer									
5-iii) Revisions and updating Revisions and updating. Clearly ment (and comparator, if applicable) evaluation process, or whe	ated, or de	escribe wh	ether the i	nterventio	n underwe	ent major changes			
Describe dynamic components such the replicability of the intervention (fo					h may hav	e an impact on			
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			
Does your paper address sub Copy and paste relevant sections from indicate direct quotes from your man information not in the ms, or briefly e Your answer	n the mar uscript), c	nuscript (ir or elaborat	e on this it	tem by pro	viding add	litional			
5-iv) Quality assurance methods Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			

You're editing your response. Sharing this URL allows others to alsoFILL OUT A NEWedit your response.RESPONSE

Does your paper address subitem 5-iv? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study									
Your answer									
5-v) Ensure replicability by personance of the screenshots/screen-capture used Ensure replicability by publishing the and/or providing flowcharts of the algorithm principle be able to replicate the stude	video, a source co gorithms (and/or p ode, and/or used. Repl	roviding ^r providing icability (i.	screensh e., other re	arts of t	he algorithms			
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers /readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

You're editing your response. Sharing this URL allows others to also edit your response.

Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Study psychiatrists had access to the entire interview video, the clinician's interview notes, and previous medical and sometimes psychiatric assessments of the patient already recorded in their EMR. Each patient's psychiatrist provided the patient's PCP with a written assessment and psychiatric treatment plan. The PCP also had continuing access to this psychiatrist by phone or email between the study consultations for up to 2 years [8, 38]. "

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"ATP assessments were conducted at 6-month intervals by an ATP trained clinician who spoke the patient's primary language, either English or Spanish [38]. This interview was video recorded using HIPAA-compliant security systems and protocols. For each ATP assessment, the clinician updated a standardized electronic form to capture notes about

You're editing your response. Sharing this URL allows others to also edit your response.

	rs					
Describe use parameters (e.g., intend recommendations were given to the u was the intervention used ad libitum.	user, e.g.,					
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sul	oitem 5·	-ix?				
Copy and paste relevant sections from indicate direct quotes from your man information not in the ms, or briefly e	uscript), c	or elaborat	e on this i	tem by pro	viding add	itional
Your answer						
5-x) Clarify the level of huma	an involv	/ement				
Clarify the level of human involvement in the e-intervention or as co-intervention or as well as "type of assistance offered medium by which the assistance is d human involvement required for the t	nt (care pr ntion (deta d, the timin elivered". rial, and tl	oviders or il number ng and free It may be he level of	and exper quency of necessary human inv	tise of pro the suppo to disting volvement	fessionals rt, how it is uish betwe required fe	involved, if any, initiated, and the en the level of
5-x) Clarify the level of huma Clarify the level of human involvemen in the e-intervention or as co-interven as well as "type of assistance offered medium by which the assistance is d human involvement required for the t application outside of a RCT setting (nt (care pr ntion (deta d, the timin elivered". rial, and tl	oviders or il number ng and free It may be he level of	and exper quency of necessary human inv	tise of pro the suppo to disting volvement	fessionals rt, how it is uish betwe required fe	involved, if any, initiated, and the en the level of
Clarify the level of human involvement in the e-intervention or as co-intervent as well as "type of assistance offered medium by which the assistance is d human involvement required for the t	nt (care pr ition (deta d, the timin elivered". rial, and tl (discuss u	oviders or il number ng and free It may be ne level of nder item	and exper quency of necessary human inv 21 – gene	tise of pro the suppo to disting volvement eralizability	fessionals rt, how it is uish betwe required fo).	involved, if any, initiated, and the en the level of

You're editing your response. Sharing this URL allows others to also edit your response.

5-xi) Report any prompts/reminders used Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 - generalizability). 1 2 3 4 5 subitem not at all important O O O O O essential Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable to this study

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

You're editing your response. Sharing this URL allows others to also edit your response.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Primary Outcomes

The primary outcomes were derived from the psychiatrists report and included the Clinical Global Impressions scale (CGI) [39] and the Global Assessment of Functioning (GAF) [40]. The CGI is a 3-item 7-point observer-rated scale that measures illness severity, global improvement or change and therapeutic response. The CGI is considered a robust measure with established validity in inpatient [41], outpatient [42], and clinical trial settings [42]. The CGI severity of illness and improvement scales are commonly used in non-drug trial settings [39]. We used the CGI severity of illness scale where 1 is normal, and 7 is among the most extremely ill patients. The GAF is a widely used rating scale to assess impairment among patients with psychiatric disorders. The GAF assesses the level of psychological, social, and occupational functioning on a 1–100 scale, with higher levels indicating better functioning [40].

Secondary Outcomes

Secondary outcomes focused on patient self-report and included the 12-Item Short Form Health Survey's (SF-12) [43] Physical Health Component Summary (PHS-12) and Mental Health Component Summary (MHS-12) scores (both scored from 0 to 100, with higher scores indicating better health) and the Patient Health Questionnaire-9 (PHQ-9) [44]. The PHQ-9 is a well validated depression scale with scores derived as the sum of 9 items (each scored from 0 [not at all] to 3 [nearly every day]; scale range 0 to 27) based directly on the diagnostic criteria for major depressive disorder in the DSM-IV (Diagnostic and Statistical Manual Fourth Edition [37]."

You're editing your response. Sharing this URL allows others to also edit your response.

apply CHERRIES items to des designed/deployed If outcomes were obtained through or and apply CHERRIES items to describ	nline ques	stionnaires	s, describe	-		
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant sections from						
Your answer						
6a-ii) Describe whether and I		se" (inclu	uding in	tensity c	of use/do	osage) was
6a-ii) Describe whether and l defined/measured/monitored Describe whether and how "use" (incl (logins, logfile analysis, etc.). Use/add reported in any ehealth trial.	d uding inte	ensity of u	se/dosage	e) was defi	ned/measi	ured/monitored
defined/measured/monitored Describe whether and how "use" (incl (logins, logfile analysis, etc.). Use/add	d uding inte	ensity of u	se/dosage mportant	e) was defi	ned/measi itcomes th	ured/monitored
defined/measured/monitored Describe whether and how "use" (incl (logins, logfile analysis, etc.). Use/add	d uding inte option me	ensity of u	se/dosage mportant	e) was defi process ou	ned/measi itcomes th	ured/monitored
defined/measured/monitored Describe whether and how "use" (incl (logins, logfile analysis, etc.). Use/add reported in any ehealth trial.	d uding inte option me 1 O Ditem 6a	ensity of u etrics are i 2 O a-ii?	se/dosage mportant	e) was defi process ou	ned/measi itcomes th	ured/monitored at should be

6a-iii) Describe whether, how was obtained	v, and w	hen qua	litative	feedbac	k from p	oarticipants
Describe whether, how, and when qua emails, feedback forms, interviews, fo			m particip	oants was	obtained (e.g., through
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text

Your answer

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes changes were made because of the DSMB outcome. "At a DSMB review in early 2018 it was noted that the dropout at 24 months was higher than anticipated. Thus, the DSMB recommended the primary end point be at 12 months and advised subsequent enrollment be limited to 12-month follow-up."

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

You're editing your response. Sharing this URL allows others to also edit your response.



Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No interim analyses were conducted on this trial. A DSMB committee convened to assess for safety and stopping criteria was defined.

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

You're editing your response. Sharing this URL allows others to also edit your response.

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The SCID established a primary Axis I diagnosis which was used as a strata for stratified randomization. Prior to enrolling the first participant, a randomization schedule for each study site was created by the study statistician."

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

" A stratified block randomization schedule was used to assign participants

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"1:1 to treatment conditions, with a set of permuted blocks of size four generated for each SCID primary Axis I categorization to reduce imbalance between groups." the study was not blinded

You're editing your response. Sharing this URL allows others to also edit your response.

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The statistician not involved in enrollment generated the list before the first participant was enrolled. "Prior to enrolling the first participant, a randomization schedule for each study site was created by the study statistician. "

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 11a-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Because of the nature of the intervention, blinding for either patients or clinicians was not

You're editing your response. Sharing this URL allows others to also edit your response.

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"								
Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".								
	1	2	3	4	5			
subitem not at all important	0	0	0	0	0	essential		

Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

11b) If relevant, description of the similarity of interventions (this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable to this study

12a) Statistical methods used to compare groups for primary and secondary

outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was

You're editing your response. Sharing this URL allows others to also edit your response.

Does your paper address CONSORT subitem 12a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study									
"Mixed-effects linear regression models [46] were used to characterize the longitudinal trajectories of primary and secondary outcomes and assess treatment effects. The interaction terms allowed us to assess intervention effects, i.e., adjusted differences in follow-up compared with baseline differences between ATP and STP."									
12a-i) Imputation techniques to deal with attrition / missing values Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).									
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			

Does your paper address subitem 12a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Analytical framework allowed participants with missing values/ mixed effects

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

You're editing your response. Sharing this URL allows others to also edit your response.

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Models for patient self-reported outcomes were similarly adjusted for a composite variable whose levels captured all possible combinations of study site, person conducting the interview (ATP interviewer or STP psychiatrist), and language of the interview. We accounted for clustering using a random effect for the patient and, whenever possible, a random effect for the referring physician." X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item) X26-i) Comment on ethics committee approval 1 2 3 4 5


		2	0	-	0	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.



You're editing your response. Sharing this URL allows others to also edit your response.

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary

outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Of 36 consenting clinicians, 28 referred at least 1 patient. Figure 1 depicts the flow of patients from screening through the primary endpoint, the 12-month follow-up. Of 401 patients assessed for eligibility, 184 were enrolled and randomized to the ATP or STP intervention. Of the 184 randomized participants, 24 (14 ATP, 10 STP) withdrew before the baseline visit and 12 (7 ATP, 5 STP) were consented to 12-month follow up. Reasons for early withdrawal included insurance changes (n = 2), decline to participate (n = 7), and loss to follow-up (n = 15). Multimedia Appendix 1: Table S1 compares the demographic and clinical characteristics for the 160 participants who completed the baseline visit and the 24 who did not." See table 1

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

YesPresented in Figure 1. consort diagram

You're editing your response. Sharing this URL allows others to also edit your response.

13b-i) Attrition diagram						
Strongly recommended: An attrition d intervention/comparator in each grou tables demonstrating usage/dose/en	p plotted	over time,				
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Figure 1. Participants flow through 12-month follow-up. ATP: Asynchronous Telepsychiatry; STP: Synchronous Telepsychiatry.


14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"patient recruitment occurring between March 2014 and September 2018" Last patient seen in September 2019

You're editing your response. Sharing this URL allows others to also edit your response.



Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial did not stop early /Not applicable

15) A table showing baseline demographic and clinical characteristics for each

group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

You're editing your response. Sharing this URL allows others to also edit your response.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Refer to Table 1. Baseline demographic and clinical characteristics of participants who completed baseline visits. Includes Age, gender, Language and education

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

You're editing your response. Sharing this URL allows others to also edit your response.

16-i) Report multiple "denom Report multiple "denominators" and p study participation [and use] threshol used more than y weeks, N participan points of interest (in absolute and rela intervention.	rovide de ds" [1], e. ts "used"	finitions: F g., N expos the interve	Report N's sed, N con ention/cor	(and effec sented, N nparator a	et sizes) "ao used more t specific p	than x times, N pre-defined time
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant sections from indicate direct quotes from your many information not in the ms, or briefly ex Refer to Figure 1 consort diagram	n the mar uscript), c xplain wh	nuscript (ir or elaborat	e on this it	tem by pro	viding add	itional
16-ii) Primary analysis should Primary analysis should be intent-to-t the appropriate caveats that this is no	reat, secc	ondary ana	lyses coul			only "users", with
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant sections from indicate direct quotes from your many information not in the ms, or briefly ex Your answer	n the mar uscript), c	nuscript (ir or elaborat	e on this it	tem by pro	viding add	itional
You're editing your response. Sharing edit your response.	g this UR	L allows o	others to	also		OUT A NEW ONSE

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes in tables 2,3 and 4. "All contrasts were estimated with 95% confidence intervals (CIs) and tested with two-sided alternatives using P<.05 as a threshold for statistical significance."

17a-i) Presentation of process outcomes such as metrics of use and intensity of

use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

You're editing your response. Sharing this URL allows others to also edit your response.

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not applicable- no binary outcomes

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No exploratory analysis preformed. Secondary analyses are presented in Supplemental tables- multimedia appendix 1.

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).



You're editing your response. Sharing this URL allows others to also edit your response.

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Adverse or unanticipated events that occurred during in the trial were reported to the IRB and the DSMB, and included 2 patient deaths from unrelated medical complications, and 2 patients who threatened self-harm. Both patients who threatened self-harm were urgently contacted by study psychiatrists to make clinical decisions on their follow-up care. The DSMB determined that neither event was study related."

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

You're editing your response. Sharing this URL allows others to also edit your response.

information not in the ms, or briefly e	uscript), c	r elaborat	e on this it	em by pro	viding add	
Your answer						
19-ii) Include qualitative feec staff/researchers	lback fr	om part	icipants	or obse	ervations	from
Include qualitative feedback from par strengths and shortcomings of the ap or uses. This includes (if available) re by the developers.	pplication,	especially	/ if they po	oint to unir	ntended/un	expected effects
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Copy and paste relevant sections from indicate direct quotes from your man information not in the ms, or briefly e Your answer	uscript), c	r elaborat	e on this it	em by pro	viding add	itional
DISCUSSION						
DISCUSSION 22) Interpretation consisten considering other relevant e NPT: In addition, take into account th expertise of care providers or centers	evidenc	e of the com		•		

Æ

22-i) Restate study questions starting with primary outcom Restate study questions and summar outcomes and process outcomes (us	nes and ize the an	proces	s outcor	mes (use	e)	-
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant sections from indicate direct quotes from your man	n the mar	nuscript (ir				
"At both 12 and 24 months follow improving patient outcomes." 22-ii) Highlight unanswered r						
Highlight unanswered new questions,	, suggest	future rese	earch.			
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address sub Copy and paste relevant sections from indicate direct quotes from your many information not in the ms, or briefly en Your answer	n the mar uscript), c	nuscript (ir or elaborat	e on this i	tem by pro	viding add	itional
ou're editing your response. Sharing	g this UR	L allows (others to	also	FILL	OUT A NEW

edit your response.

RESPONSE

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



Does your paper address subitem 20-i? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"There were study limitations. We had anticipated a 25% dropout for the 2-year study. However, 67 (31 ATP, 36 STP) of the 160 patients who completed baseline withdrew from the study at either 6 or 12 months (42%)..." see discussion section where this is addressed at length

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

You're editing your response. Sharing this URL allows others to also edit your response.



OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"ClinicalTrials.gov identifier: NCT02084979."

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24?*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"ClinicalTrials.gov identifier: NCT02084979."

25) Sources of funding and other support (such as supply of drugs), role of funders

You're editing your response. Sharing this URL allows others to also edit your response.

Does your paper address CC Copy and paste relevant sections fror indicate direct quotes from your man information not in the ms, or briefly e "Supported by the Agency for He	n the man uscript), o xplain why	nuscript (ir r elaborate y the item	nclude quo e on this if is not app	tem by pro licable/rel	viding add evant for y	itional ⁄our study
X27) Conflicts of Interest (n	ot a CO	NSORT	item)			
X27-i) State the relation of the In addition to the usual declaration of study team towards the system being identical with the developers/sponso	interests evaluated	(financial d, i.e., stat	or otherw e if the au	vise), also s	state the re	elation of the
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

About the CONSORT EHEALTH checklist

You're editing your response. Sharing this URL allows others to also edit your response.

As a result of using this checklist, did you make changes in your manuscript? * yes, major changes yes, minor changes
What were the most important changes you made as a result of using this checklist? Your answer
How much time did you spend on going through the checklist INCLUDING making changes in your manuscript * this checklist application is very difficult to use in the current format
As a result of using this checklist, do you think your manuscript has improved? * yes no Other:

You're editing your response. Sharing this URL allows others to also edit your response.

Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
O yes
O no
O Other:

Any other comments or questions on CONSORT EHEALTH

Your answer

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit ! Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

Google Forms

You're editing your response. Sharing this URL allows others to also edit your response.